Zai Lab Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| 1ZLB.F | ZYME | 6HN.F | VIR | 1875.HK | INVA | |
|---|---|---|---|---|---|---|
| Market cap | 2.32B | 1.81B | 813.26M | 1.56B | 2.45B | 1.31B |
| P/E (TTM) | — | 50.3 | — | — | — | 7.8 |
| Forward P/E | — | 55.0 | — | -3.5 | 41.0 | 8.3 |
| Price/book | 4.2 | 7.2 | 1.0 | 1.6 | 3.6 | 1.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +11.30% | +11.82% | −41.20% | +56.16% | +84.72% | −12.17% |
| Today | −5.58% | −2.68% | −10.16% | −5.41% | +1.50% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 1ZLB.F news ›Zai Lab: The China Engine Pays The Bills, Zoci Could Pay The Upside (Initiating Buy)
China Summary I initiate Zai Lab at Buy with a $43 target; the China franchise provides a floor, while Zoci's global potential is underappreciated. ZLAB’s China business faces price cuts and ZEJULA competition, but sequential product…
Zai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of Choice
China Summary Zai Lab looks underappreciated as the wholly owned developer of zoci, a potential DLL3 treatment backbone, rather than merely a China distributor. Amgen and Boehringer are funding zoci combination studies; first-line data…
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. - TIVDAK is the first antibody-drug conjugate (ADC) approved for the treatment of previously…
Zai Lab Announces Participation in Investor Conferences in November 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2026: UBS…
Zai Lab Limited announced that it has received $249.9336 million in funding from a group of investors
On November 9, 2026, Zai Lab Limited has closed the transaction. The company has received $249,933,600 from 25 investors pursuant to Regulation D. The sales commission fees of $7,498,008 was paid. Zai Lab Limited announced that it has…
Zai Lab Q3 Performance Meets Expectations With Pivotal 2027 Ahead, UBS Says
Zai Lab's Q3 results were broadly in line with expectations, with progress across its global drug pipeline, UBS said in a note emailed Friday. The analysts said 2027 is expected to be a pivotal year,... Zai Lab Q3 Performance Meets…
Zai Lab Says Experimental Drug Reduced Activity of Protein Linked to Atopic Dermatitis by at Least 90%
Zai Lab said Friday that a single dose of its experimental drug ZL-1503 showed reduced activity in a protein linked to atopic dermatitis by at least 90% for up to 12 weeks in a phase 1 trial involving... Zai Lab Says Experimental Drug…
Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript
Transcripts China Zai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans Transcript Nov 13, 2026, 11:39 AM ETZai Lab Limited (ZLAB) StockSA Transcripts163.02K Followers Zai Lab Limited (ZLAB)…
Zai Lab Q3 Earnings Call Highlights
Posted by Kim Johansen on Nov 9th, 2026 Zai Lab (NASDAQ:ZLAB) reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate…
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab anticipates major catalysts in 2027 across multiple global programs with transformative potential: Conference call and webcast today, November 5, 2026, at 8:00 a.m. ET (9:00 p.m. HKT) SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com7
- marketscreener.com6
- biospace.com2
- defenseworld.net1
- markets.financialcontent.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.